within Pharmacolibrary.Drugs.D_Dermatologicals.D06A_AntibioticsForTopicalUse.D06AX11_Rifaximin;

model Rifaximin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.01,
    Cl = 8.944444444444446e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.011699999999999999,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016666666666666666,
    Tlag = 0);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Rifaximin</td></tr><tr><td>ATC code:</td><td>D06AX11</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>11.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>32.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Rifaximin is a non-systemic, semisynthetic antibiotic derived from rifamycin. It is primarily used to treat travelers' diarrhea caused by noninvasive strains of Escherichia coli and to reduce the risk of hepatic encephalopathy in patients with liver disease. It is also used in the management of irritable bowel syndrome with diarrhea (IBS-D). Rifaximin is approved for use in several countries, including the US and Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers following oral administration; non-compartmental analysis.</p><h4>References</h4><ol><li><p>Scarpignato, C, &amp; Pelosini, I (2005). Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. <i>Chemotherapy</i> 51 Suppl 1 36–66. DOI:<a href=\"https://doi.org/10.1159/000081990\">10.1159/000081990</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15855748/\">https://pubmed.ncbi.nlm.nih.gov/15855748</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D06AX11 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Rifaximin;
